The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as ...
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates ...
I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast.
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...
Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan ...
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...
The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.
Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, ...
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback